UroMems SAS
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
UroMems SAS - overview
Established
2011
Location
Grenoble, -, France
Primary Industry
Medical Devices & Equipment
About
Based in France, SAS UroMems specializes in advanced medical devices focused on treating severe stress urinary incontinence (SUI) through innovative implantable technology. SAS UroMems, founded in 2011 in Grenoble, France, develops medical technology aimed at addressing urinary incontinence. The co-founders, Hamid LAMRAOUI (CEO), Pierre Mozer and Stephane Lavallee, have established the company as a significant player in the field. In May 2026, SAS UroMems raised USD 60 million in venture funding from ICONIQ Capital.
UroMems focuses on developing advanced medical technologies, specifically its flagship product, UroActive™, which addresses severe stress urinary incontinence (SUI) for both genders. The implantable device is engineered to adapt automatically to individual patient needs, enhancing their quality of life. Currently in clinical investigations, UroActive™ aims to enter broader markets upon successful evaluation and regulatory approval, collaborating closely with urologists and healthcare providers in North America and Europe. In 2020, UroMems reported revenue of USD 0.
00, indicating a focus on product development rather than sales at this stage. The company’s revenue model relies on partnerships with healthcare providers and clinical institutions, where revenues are expected to arise from UroActive™ sales as they progress through clinical stages and reach commercialization. The company plans to utilize the May 2026 funding to conduct key clinical trials for its implant technology and collect the necessary data for regulatory approval in several countries.
Current Investors
Wellington Partners, CEA Investissement, b2venture
Primary Industry
Medical Devices & Equipment
Sub Industries
Healthcare Specialists, Medical Devices & Equipment, Therapeutic Devices
Website
www.uromems.com/
Verticals
HealthTech, Manufacturing
Company Stage
Series C
Total Amount Raised
Subscriber access only
UroMems SAS - financials
| Fiscal Year Ended | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | - | - | - | - | - | - | - | - |
| % Revenue Growth (YoY) | - | - | - | - | - | - | - | - |
| EBITDA (USD) | (684,536) | (1,317,075) | - | - | - | - | - | - |
| Operating Income (USD) | (804,053) | (1,602,588) | - | - | - | - | - | - |
| Operating Margin | - | - | - | - | - | - | - | - |
| % EBITDA Margin | - | - | - | - | - | - | - | - |
| NET Income (USD) | (669,940) | (1,437,964) | (2,294,235) | (2,685,847) | (3,395,849) | - | - | - |
| % Net Margin | - | - | - | - | - | - | - | - |
UroMems SAS - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Unspecified Round | Completed | UroMems SAS | - | ||||||||
| Series C | Completed | UroMems SAS | - | ||||||||
| Series B | Completed | UroMems SAS | - | ||||||||
| Venture Debt | Completed | UroMems SAS | - | ||||||||
| Series B | Completed | UroMems SAS | - |
Displaying 1 - 5 of 9
UroMems SAS - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.